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Background: KPC-producing Klebsiella pneumoniae (KPCKP) is a threat for patients 
admitted to healthcare institutions.
Objectives: To assess the efficacy of several decolonization strategies for KPCKP 
rectal carriage.
Methods: Observational study performed in a 750-bed university center from July to 
October 2018 on the efficacy of a 10-day non-absorbable oral antibiotic (NAA) regimen 
(colistin 10 mg/ml, amikacin 8 mg/ml, and nystatin 30 mg/ml, 10 ml/6 h) vs. the same 
regimen followed by a probiotic (Vivomixx®) for 20 days in adult patients with KPCKP 
rectal colonization acquired during an outbreak.
Results: Seventy-three patients colonized by KPCKP were included, of which 21 (29%) 
did not receive any treatment and 52 (71.2%) received NAA either alone (n = 26, 35.6%) 
or followed by a probiotic (n = 26, 35.6%). Eradication was observed in 56 (76.7%) patients 
and the only variable significantly associated with it was not receiving systemic antibiotics 
after diagnosis of rectal carriage [22/24 (91.6%) vs. 34/49 (69.3%), p = 0.04]. Eradication 
in patients receiving NAA plus probiotic was numerically but not significantly higher than 
that of controls [23/26 (88.4%) vs. 15/21 (71.4%), p = 0.14] and of those receiving only 
NAA (OR = 3.4, 95% CI = 0.78–14.7, p = 0.09).
Conclusion: In an outbreak setting, rectal carriage of KPCKP persisted after a mean of 
36 days in about one quarter of patients. The only factor associated with eradication was 
not receiving systemic antibiotic after diagnosis. A 10-day course of NAA had no impact 
on eradication. Probiotics after NAA may increase the decolonization rate, hence deserving 
further study.
Keywords: decolonization, probiotic, non-absorbable antibiotic regimen, KPC-2 producing Klebsiella pneumoniae, 
outbreak
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INTRODUCTION
Infections caused by KPC-2 producing Klebsiella pneumoniae 
(KPCKP) are an increasing threat for patients admitted to healthcare 
institutions (McConville et  al., 2017). According to the World 
Health Organization (WHO), multidrug-resistant microorganisms, 
including third-generation cephalosporin-resistant Enterobacterales 
(3GCephRE), carbapenem-resistant Enterobacterales (CRE), 
Acinetobacter baumannii, and Pseudomonas aeruginosa, are a critical 
priority for new antibiotic research and development (Tacconelli 
et  al., 2018). Hand hygiene is the most effective single measure 
to prevent patient-to-patient transmission of multidrug resistant 
Gram-negative bacteria (MDR-GNB); cleaning and disinfection of 
surfaces, contact precautions and decolonization also contribute 
to prevention (Tacconelli et  al., 2014).
Decolonization therapy, defined as any measure that leads to 
loss of detectable MDR-GNB carriage at any site, has a very low 
level of evidence due to the inconsistent results of the studies 
assessing it. In this context, a European guideline with 
recommendations for decolonizing regimens targeting MDR-GNB 
carriers in all settings was published in 2019 (Tacconelli et  al., 
2019). After reviewing 11 articles, the panel made a conditional 
recommendation against routine decolonization of CRE carriers. 
Nevertheless, on the basis of the limited evidence of its efficacy 
in high-risk patients, (Saidel-Odes et  al., 2012; Oren et  al., 2013) 
further good-quality clinical studies are needed in order to define 
more precisely the infection risk in populations such as colonized 
hematological patients and solid organ transplant recipients. These 
studies should set the basis for designing clinical decolonization trials.
In addition to non-absorbable antibiotics, other decolonization 
strategies deserve consideration. Giving the key role of dysbiosis 
on the loss of colonization resistance, microbiome-modifying therapies 
are worth exploring. These include fecal microbiota transplantation 
(FMT), probiotics, and prebiotics, and a range of therapies in 
between (Catho and Huttner, 2019; Feehan and Garcia-Diaz, 2020). 
In regards to probiotics, few and relatively small clinical trials have 
been so far unable to show any effect in preventing the acquisition 
of MDR microorganisms during traveling (Dall et  al., 2019) or 
in promoting decolonization in carrier patients (Kwon et al., 2015; 
Salomão et  al., 2016; Ljungquist et  al., 2020). In addition, there 
is still some concern that manipulation of the microbiome could 
lead to unintended consequences including infections, particularly 
in immunosuppressed individuals and the critically ill.
An outbreak of KPCKP occurred during the summer 2018  in 
our hospital and, at some point during its evolution, the infection 
control team decided to include a decolonization regimen as part 
of the multifaceted control strategy. The study aim was to assess 
the factors associated with short-term eradication of rectal carriage 
with special emphasis on the role of a non-absorbable oral antibiotic 
(NAA) regimen and a probiotic.
MATERIALS AND METHODS
Setting, Study Design, and Patients
This was an observational study conducted in a 750-bed 
university hospital in Barcelona, Spain from July to October 
2018 and carried out in the context of a KPCKP outbreak.
During the outbreak period, active screening by rectal 
swabbing for KPCKP was done on admission and weekly 
thereafter to all patients admitted to high-risk wards until no 
new cases were detected for at least 2 consecutive weeks. All 
patients with a positive rectal swab for KPCKP were subjected 
to contact precautions and enrolled progressively into three 
different interventions according to the availability of a poly-
antibiotic oral solution made at the hospital’s pharmacy and 
a commercial probiotic, as follows:
i. Control group: The control group was composed of 
colonized patients who did not receive decolonization treatment 
(DT) as they were discharged before the beginning of 
the intervention.
ii. Non-absorbable antibiotic regimen (NAA): Patients in 
this group received 10  ml every 6  h of a mixture of colistin 
sulfate 10 mg/ml plus amikacin 8 mg/ml plus nystatin 30 mg/ml 
for 10  days.
iii. NAA plus probiotic regimen: The third group received 
the above mentioned NAA regimen followed by a probiotic 
(Vivomixx®) once a day for 20  days. Vivomixx® contains a 
combination of four Lactobacillus (Lactobacillus paracasei DSM 
24733, Lactobacillus acidophilus DSM 24735, Lactobacillus 
delbrueckii ssp. bulgaricus DSM 24734, and Lactobacillus 
plantarum DSM 24730), three Bifidobacteria (Bifidobacterium 
breve DSM 24732, Bifidobacterium longum DSM 24736, and 
Bifidobacterium infantis DSM 24737), and Streptococcus 
thermophilus DSM 24731 at a concentration of 450 billion live 
lyophilized bacteria per sachet.
Non-absorbable oral antibiotic treatment started immediately 
after colonization detection and the probiotic was initiated 24  h 
after the last dose of NAA. Day 0 was considered the day when 
NAA regimen was completed (in decolonized patients) or the 
day of first carriage detection (in non-decolonized patients). All 
patients were followed up for at least 1  month. A control rectal 
swab was performed 1  month after day 0  in the three groups.
Patients younger than 18  years, HIV infected and those 
with solid and hematopoietic stem cell transplantation (HSCT) 
did not receive the probiotic strategy due to safety concerns.
The study was approved by the Hospital Ethics Committee 
(HCB/2020/0704). Written informed consent for the non-absorbable 
antibiotic regimen was waived because it was considered routine 
care for the purpose of controlling the outbreak in agreement 
with the policy endorsed by the Hospital Infection Control Team. 
Informed consent was signed by patients taking the probiotic.
Clinical Variables, Definitions, and 
Outcomes
The following variables were collected from each patient: age, 
sex, chronic underlying diseases, chronic disease severity 
according to the Charlson index, performance status according 
to Barthel index, use of concomitant systemic antibiotic therapy 
during the intervention period, development of KPCKP infection, 
decolonization regimen, adverse reactions to the decolonization 
regimen and mortality.
Intestinal colonization was defined as the isolation from a 
rectal swab of a KPCKP strain phenotypically identical to the 
epidemic clone. Eradication was defined as the absence of 
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KPCKP in the 1-month control rectal swab. Clinical infections 
were defined according to the CDC criteria. Antibiotics were 
considered active against KPCKP when the strain was susceptible 
according to the antibiogram. The main outcome variable was 
the eradication rate.
Microbiology
Rectal swabs were processed at the local Microbiology department 
laboratory. They were plated on MacConkey agar (Becton 
Dickinson, Heidelberg, Germany) with an Aztreonam disk (30 μg), 
chromID ESBL agar (bioMérieux, Marcy l’Etoile, France), and 
chromID CARBAsmart (bioMérieux). Colonies grown on ESBL 
and CARBAsmart agars were identified using MALDI-TOF MS 
(matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry; Bruker, Bremen, Germany). Antibiotic Susceptibility 
testing was done by disk diffusion and broth microdilution 
methods using the Phoenix System (Becton Dickinson). The 
results were interpreted according to EUCAST guidelines (EUCAST 
8.0, 2018). Carbapenemase production was confirmed using an 
immunochromatographic assay (NG-test CARBA5; NG Biotech, 
Guirpuy, France) from grown colonies detecting KPC, NDM, 
VIM, IMP, and OXA-like carbapenemases. Characterization of 
blaKPC gene was performed by PCR, followed by DNA sequencing.
Statistical Methods
Groups of interest were compared with a univariate analysis by 
Chi-squared test, Fisher’s exact test, or ANOVA as appropriate. 
Those variables with a p-value lower than 0.2  in the bivariate 
analysis were introduced in a multivariate logistic regression 
model to determine the factors independently associated with 
KPCKP eradication. A value of p < 0.05 was considered significant. 
Analyses were performed using IBM SPSS Statistics version 24.
RESULTS
There were 93 patients involved in the KPCKP outbreak. KPC 
carbapenemase production was detected using lateral flow assay 
and the presence of blaKPC-2 was confirmed by PCR and 
sequencing (Yigit et  al., 2008). The complete microbiological 
study of the outbreak strains is under review prior to publication.
A total of 73 patients had a control rectal swab 1  month 
after completion of NAA regimen or first carriage detection 
and were included in the study: 21  in the control group, 26  in 
the NAA group, and 26  in the NAA plus probiotic group 
(Figure  1). Four patients died before having the control swab 
taken and were excluded (one in the control group, two in 
the NAA, and one in the probiotic group). Table  1 shows the 
clinical features of the patients. There were significant differences 
among groups in the frequency of patients with solid and 
HSCT as they were excluded from the NAA plus probiotic 
group (p  =  0.022 and 0.039, respectively). Time elapsed from 
day 0 to 1-month control rectal swab was 37  ±  12  days in 
the control group and 41  ±  21  in the other two groups.
In the whole series, eradication rate at 1 month of follow-up 
was 76.7% (56 patients). Factors associated with eradication 
are shown in Table  2. A significant association was observed 
FIGURE 1 | Flow chart of patients included in the study.
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TABLE 2 | Univariate analysis of factors associated with eradication.
Characteristic Eradication (n = 56) No eradication (n = 17) OR (95% IC) p
Age, mean ± SD 61.8 ± 13.8 63.4 ± 15.1 - 0.67
Female sex 30 (54%) 10 (59%) 0.8 (0.3–1.9) 0.7
Age-adjusted Charlson index, 
median (IQI)
5 (3–7) 4 (2–7.5) - 0.40
Barthel index, median (IQI) 100 100 - 0.81
HSCT, n (%) 3 (5%) 1 (6%) 0.9 (0.16–5.3) 0.93
Solid organ transplantation, n (%) 9 (16%) 0 - 0.078
Receipt of systemic antibiotics, n (%) 34 (61%) 15 (88%) 0.2 (0.042–0.99) 0.041
Decolonization treatment, n (%)
- None
- NAA












IQI, interquartile interval; HSCT, hematopoietic stem cell transplantation; and NAA, non-absorbable oral antibiotic.
between receiving systemic antibiotics after diagnosis of rectal 
carriage and lack of eradication (the 1-month control rectal 
swab was negative in 34 (69.3%) of 49 patients taking antibiotics 
vs. 22 (91.6%) of 24 patients not receiving them (OR  =  0.2, 
95% CI  =  0.042–0.99, p  =  0.04).
Although the intervention group was not significantly associated 
with the primary outcome, the rate of decolonization at 1-month 
in patients receiving NAA plus probiotic was numerically higher 
than that of controls [23/26 (88.4%) vs. 15/21 (71.4%), OR = 3, 
95% CI  =  0.66–14, p  =  0,16] and of those receiving NAA only 
(OR  =  3.4, 95% CI  =  0.78–14.7, p  =  0.09).
An exploratory multivariate logistic regression analysis retained 
two variables in the model: receiving systemic antibiotics 
(OR = 0.14, 95% CI = 0.03–0.73, p = 0.02) and the interaction 
of the NAA plus probiotic group with the administration of 
systemic antibiotics (OR  =  4.3, 95% CI  =  0.8–25, p  =  0.086). 
This interaction reflects the fact that taking NAA plus probiotic 
was almost significantly associated with a higher eradication 
rate in the subgroup of patients that received systemic antibiotics 
(14/16, 87% vs. 20/33, 61%; OR  =  4.5, 95% CI  =  0.9–23, 
p  =  0.055), however, this trend was not observed in patients 
not receiving systemic antibiotics (9/10, 90% vs. 13/14, 93%; 
OR  =  0.69, 95% CI  =  0.04–12.5, p  =  1).
Clinical infections were diagnosed in 13 (17.8%) patients. 
In nine of them, the infection was present on detection of 
rectal carriage and in four it appeared more than 48  h later. 
Isolates proceeded from urine culture in seven patients; blood 
cultures in three, and ascitic fluid, osteoarticular tissue, and 
endometrial aspirate in one each. After detection of rectal 
carriage, no clinical infections were observed in the control 
group, three (11.5%) were found in the NAA group (urinary 
tract infection, spontaneous bacterial peritonitis, and bloodstream 
infection) and one (3.8%) in the NAA plus probiotic group 
(urinary tract infection). These last four patients achieved 
eradication in the 1-month control swab.
Some patients complained of the bad taste of the NAA 
solution, but not other adverse events were reported. Both 
the 17 KPCKP strains isolated from the 1-month control rectal 
swab and the four from the clinical samples remained susceptible 
to colistin and amikacin.
DISCUSSION
The results of this observational study suggest that in terms 
of KPCKP eradication from stools after 1  month of detection 
or after finishing a 10-day NAA course, taking a NAA solution 
consisting of colistin and amikacin was not better than not 
taking it. However, there is also some suggestion that in 
comparison with no treatment or NAA alone, the administration 
TABLE 1 | Characteristics of patients colonized by KPCKP according to the intervention group.
Characteristics No treatment group (n = 21) NAA group (n = 26) NAA plus probiotic group 
(n = 26)
p
Age (mean ± SD) 65.6 ± 10.2 57.3 ± 15.6 64.2 ± 14.3 0.085a
Female sex, n (%) 13 (62%) 15 (58%) 12 (46%) 0.52
Age-adjusted Charlson index, median (IQI) 5 (3.5–8.5) 4 (3–7) 5 (2.5–6) 0.34b
Barthel index, median (IQI) 100 100 100 0.30b
HSCT, n (%) 0 4 (15%) 0 0.022
Solid organ transplantation, n (%) 3 (14%) 6 (23%) 0 0.039
Receipt of systemic antibiotics, n (%) 12 (57%) 21 (81%) 16 (61%) 0.173
NAA, non-absorbable oral antibiotic; IQI, interquartile interval; and HSCT, hematopoietic stem cell transplantation. 
aANOVA.
bKruskal-Wallis.
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of a probiotic after the NAA regimen may increase the 1-month 
decolonization rate. In addition, this study indicates that the 
main factor deterring eradication is exposure to systemic 
antibiotics after carriage detection, and that the beneficial effect 
of the probiotic-containing regimen seems to be  limited to 
the subgroup of patients exposed to them.
Failure of NAA to achieve stable eradication of multiple-drug 
resistant Gram-negative bacilli in general or KPCKN in particular 
has been previously described (Saidel-Odes et  al., 2012; Lübbert 
et  al., 2013; Bar-Yoseph et  al., 2016). For KPCKP decolonization, 
the most commonly used regimens have been based on colistin 
(1 vs. 2  MU four times daily) and/or gentamicin (80  mg four 
times daily). The clinical guidelines of ESCMID-EUCIC suggest 
designing decolonization assays with oral colistin sulfate (50  mg 
four times daily) with or without gentamicin sulfate (80  mg four 
times daily; Tacconelli et al., 2019). However, this recommendation 
may be questionable. Some authors suggest that 100 mg of colistin 
sulfate (about 67  mg of colistin base or 2  MU) every 6  h may 
be the most effective dosage (Silvestri et al., 2013). Previous studies 
on neutropenic patients had suggested that when colistin was 
given alone, 800 mg/day was perhaps the most appropriate regimen 
(Clasener et  al., 1987). It is of note that inactivation of colistin 
in feces (90–95%) is significantly reduced when co-administered 
with tobramycin and this was the rationale for combining 
aminoglycosides with lower colistin dosages (Clasener et al., 1987). 
The NAA solution used in the present study contained 2  MU 
per dose and yet, we did not see any effect per se on the eradication 
rate. The reason for the accompanying aminoglycoside being 
amikacin is that this oral solution was designed as the decolonizing 
regimen for selected high-risk patients carrying MDR-GNB with 
high rates of resistance to gentamicin and tobramycin.
In the present study, the lack of efficacy of NAA alone was 
mainly explained by the high rate of 1-month spontaneous 
eradication. The meta-analysis performed by Bar-Yoseph et  al. 
(2016) included six and five studies for a total of 239 and 172 
patients to assess the rate of CRE persistent carriage among 
healthcare residents at 3 and 12  months, respectively. The 
carriage decreased from 74.6% at 3 months to 34.6% at 12 months. 
Feldman et  al. (2013) followed 125 KPCKP carriers monthly 
for 3 months. Spontaneous decolonization was observed in 48% 
at 1 month and in 52% at 2 months. However, in the persistent 
carriers, 70% remained positive at 6  months (Feldman et  al., 
2013). In our study, we  observed a spontaneous decolonization 
rate of 71% (15/21), which was higher than that reported by 
others. We  do not have a satisfactory explanation for these 
discrepancies. The absence of clinical infection in this group 
may suggest a lower bowel burden than in the other groups.
The lack of NAA efficacy in the present study does not 
automatically dismiss a given decolonization strategy as clinically 
useless. Even without achieving stable eradication, NAA can 
transitorily decrease the load of the colonizing microorganisms 
below the threshold burden for clinical infection or effective 
transmission. Oral decontamination with aminoglycosides has 
been associated with a lower risk of infections and mortality 
in high-risk patients colonized by colistin-resistant KPCKP 
(Machuca et al., 2016). In our study, the risk of clinical infection 
was low and did not seem to be  significantly influenced by 
the decolonization strategy. This supports the recommendation 
that only patients with a well-defined high risk of infection 
should be  the focus of any decolonization therapy.
In this study, the complementation of the NAA with a probiotic 
increased the eradication rate (from 33/47, 70.2% in the control 
or NAA groups to 23/26, 88.4% in the NAA plus probiotic 
group, OR  =  3.25, 95% CI  =  0.8–13, p  =  0.07), but almost 
exclusively in patients receiving systemic antibiotics after carriage 
diagnosis. Over the last 10  years there has been an increasing 
public and scientific interest in the administration of probiotics 
to prevent or treat diseases. Regarding MDR-BGN decolonization, 
clinical evidence is still limited. A randomized study in 103 ICU 
patients published in 2015 did not find significant differences 
in acquisition or loss of MDR organisms including Pseudomonas 
aeruginosa and ESBL or CRE, between the group of patients 
that received Lactobacillus rhamnosus GG (one capsule containing 
1010  CFU every 12  h for 14  days) and the one that did not 
(Kwon et al., 2015). In another randomized trial, the administration 
of a symbiotic (1010  CFU Lactobacillus bulgaricus plus 1010  CFU 
L. rhamnosus plus fructo-oligosaccharides twice a day for 1 week) 
or placebo to 101 evaluable hospitalized patients colonized by 
MDR-GNB was not associated with improved rates of 
decolonization or infection (16.7% in the treated group and 20.7% 
in the control group, p  =  0.60; Salomão et  al., 2016). Lastly, in 
a more recently published randomized trial, Vivomixx® (the same 
product used in the present study) or placebo were administered 
to 80 ambulatory patients colonized by ESBL-Enterobacterales 
(mainly Escherichia coli) with poor results (12.5% eradication 
rate with the probiotic vs. 5% with placebo, p  =  0.24; Ljungquist 
et  al., 2020). Regarding KPCKP, a small pilot trial has been 
mentioned in an Italian journal in which 36 elderly frail hospitalized 
patients were randomized to receive high-dose probiotic and 
psyllium for 14  days or standard care. The authors reported a 
significant reduction in carriage rate in the probiotic group during 
hospitalization (53 vs. 12%, p  =  0.009; Nouvenne et  al., 2015).
We found that exposure to systemic antibiotics was the 
main factor associated with no eradication. This is not unexpected 
for antibiotics with poor in vitro activity against KPCKP or 
for in vitro active agents achieving low concentrations in the 
intestinal lumen. Systemic antibiotics probably perpetuate 
dysbiosis and increase the bacterial burden of resistant 
microorganisms (Wang et  al., 2017), making them even less 
eradicable by NAA. Most remarkable was our observation that 
the probiotic increased the eradication rate almost exclusively 
in patients taking systemic antibiotics after the diagnosis of 
carriage. It is perhaps in this unfavorable scenario for eradication, 
where NAA regimens are insufficient and could be  improved 
with additional interventions directed to restore the integrity 
of the gut with a healthy colonic microbiota (De Rosa et al., 2015).
Development of resistance to the components of the 
decolonization regimen is of particular concern. Machuca et al. 
(2016) found that a significantly higher proportion of patients 
undergoing decolonization had gentamicin-resistant isolates in 
follow-up cultures than those not treated (13 vs. 3%; p = 0.008). 
In the Lübbert et  al. (2013) and Oren et  al. (2013) studies, 
14% (7/50) and 28% (4/14) of patients, respectively, developed 
secondary resistance to decolonizing agents. Emergence of 
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resistance may be more frequent if monotherapy is used (Oostdijk 
et al., 2013). In our experience, the KPCKP strain was susceptible 
to both colistin and amikacin and, as reported by others (Saidel-
Odes et  al., 2012), no resistance to these antibiotics developed.
The most important limitations of the study are its 
observational design, the relatively low number of patients, its 
unicentric characteristic and the short follow-up with eradication 
defined as only one negative swab at 1  month. In addition, 
the exclusion from administering the probiotic to solid organ 
and hematopoietic stem cell transplantation patients added 
heterogeneity to the intervention groups. Lastly, neither 
quantitative studies to measure the impact of the interventions 
on fecal KPCKP load nor microbiota analysis were done.
CONCLUSION
In fecal carriers of KPCKP, decolonization with a 10-day 
NAA regimen based on colistin and amikacin was not effective 
for increasing the eradication rate at 1  month of follow-up. 
However, the administration of a probiotic for 20  days after 
the conclusion of the NAA regimen was associated with a 
numerically higher eradication rate, particularly in patients 
who received systemic antibiotics after diagnosis of rectal 
carriage. No effect on the rate of clinical infections was noted. 
The present study supports current recommendations against 
the systematic use of NAA in patients colonized by MDR-GNB, 
which should be  focused on populations with documented 
high risk of infection. In our opinion, further studies are 
needed to examine the efficacy of giving probiotics after a 
NAA regimen, particularly in colonized patients who have 
to receive systemic antibiotics.
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